Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816432) titled 'A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy' on Sept. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Longbio Pharma (Suzhou) Co., Ltd.
Condition:
Food Allergy
Wheat Hypersensitivity
Intervention:
Biological: LP-003 Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 4, 2026
Target Sample Size: 12
Countries of Recruitment:...